ライフサイエンスコーパス: 18F-FDG

1 18F-FDG incorporation was significantly increased by 30

2 18F-FDG incorporation, the initial rate of O-methyl-D-gl

3 18F-FDG PET has excellent diagnostic accuracy in Hurthle

4 18F-FDG PET has proved useful in the staging and follow-

5 18F-FDG PET has reached widespread application in the as

6 18F-FDG PET is an early predictor of survival in patient

7 18F-FDG PET is increasingly being used to monitor the ea

8 18F-FDG PET offers the radiation oncology community the

9 18F-FDG PET scans were reviewed and compared with all av

10 18F-FDG PET/CT (visual analysis) detected residual nodal

11 18F-FDG PET/CT findings were correlated with the finding

12 18F-FDG PET/CT findings were validated by biopsy, histop

13 18F-FDG PET/CT has rapidly become a widely used imaging

14 18F-FDG PET/CT results were true-negative in 19 patients

15 18F-FDG PET/CT scans of gluteal and quadriceps muscle ar

16 18F-FDG PET/CT was true-positive in 4 and false-positive

17 18F-FDG uptake is more variable, with 65% of metabolical

18 18F-FDG uptake was particularly high in subjects with pe

19 18F-FDG uptake was quantified as Ki, calculated by 3-com

20 18F-FDG uptake was significantly higher in the carotid a

21 18F-FDG-PET-CT scans revealed almost complete inhibition

22 d 6 thoracic (thoracic aortic), who had >/=1 18F-FDG positron emission tomography/computed tomography

23 agreement of +/-0.21 (18F-NaF) and +/-0.13 (18F-FDG) for maximum tissue-to-background ratios.

24 ts (18F-NaF: 2.87+/-0.82 versus 1.55+/-0.17; 18F-FDG: 1.58+/-0.21 versus 1.30+/-0.13; both P<0.001).

25 grade 3, and 16 patients (10.7%) had grade 4 18F-FDG uptake for DSD.

26 Abnormal 18F-FDG uptake was assessed visually and by measuring th

27 formation, PET/CT detected sites of abnormal 18F-FDG uptake having an SUVmax of greater than 5.

28 residual lymphadenopathy, a lack of abnormal 18F-FDG uptake in these nodes also excludes viable tumor

29 Sites of abnormal 18F-FDG uptake with a maximum standardized uptake value

30 , femoral, and carotid arteries 90 min after 18F-FDG administration.

31 PET with the glucose analog 18F-FDG is increasingly being used to monitor the effect

32 of 11 patients who had both positive CT and 18F-FDG PET findings, 18F-FDG PET revealed additional si

33 racted from CT, 18F-FDG PET, and both CT and 18F-FDG PET.

34 s 0, 3, 7, 14, and 21) using 18F-FPPRGD2 and 18F-FDG.

35 on and computed tomography using 18F-NaF and 18F-FDG radiotracers.

36 We compared 18F-NaF and 18F-FDG uptake with histological characterization of the

37 their coronary calcium score and 18F-NaF and 18F-FDG uptake.

38 stenosis) were administered both 18F-NaF and 18F-FDG.

39 A three-dimensional brain phantom and 18F-FDG patient studies are used to evaluate image quali

40 x computed by finite element simulations and 18F-FDG uptake were evaluated in a total of 68 examinati

41 Technetium-99m-ECD SPECT and 18F-FDG PET showed regional luxury perfusion at the left

42 y the glucose metabolic rate in small-animal 18F-FDG PET studies.

43 ata and 0 or 1 blood sample for small-animal 18F-FDG PET studies.

44 o determine the optimal measures of arterial 18F-FDG uptake for future studies.

45 Even though nonspecific tracers such as 18F-FDG visualize certain normal anatomic structures, th

46 cause it generally has lower iodine avidity, 18F-FDG PET has been suggested as a more accurate imagin

47 Because 18F-FDG is also used in baseline staging PET/CT scans an

48 There was no significant correlation between 18F-FDG uptake and CD68 staining (r=-0.43; P=0.22).

49 vestigate whether correlations exist between 18F-FDG uptake of primary breast cancer lesions and pred

50 e improved by extending the interval between 18F-FDG administration and PET data acquisition.

51 ed from 22 institutions underwent whole-body 18F-FDG PET, including dedicated PET of the brain, after

52 patients >18 y old, referred for whole-body 18F-FDG PET/CT for evaluation of known or suspected mali

53 ardium) were successfully extracted for both 18F-FDG and 1-11C-acetate in rats.

54 Melanoma metastases were detected by 18F-FDG PET, 9-[4-(18)F-fluoro-3-(hydroxymethyl)butyl]gu

55 by immune cells and subsequent detection by 18F-FDG PET.

56 of cortical or subcortical hypometabolism by 18F-FDG PET is an unfavorable predictor.

57 associated glucose metabolism as measured by 18F-FDG uptake of the primary breast cancer lesions.

58 nodes on the left side was detected only by 18F-FDG imaging.

59 negative, thyroglobulin-positive patients by 18F-FDG PET/CT may aid in the clinical management of sel

60 ng to diagnostic classifications provided by 18F-FDG PET at baseline and clinical diagnoses after a m

61 Risk stratification by 18F-FDG PET appears to be at least as predictive as the

62 best-fitting model to assess SMGU studied by 18F-FDG.

63 und effect on Patlak kinetics and calculated 18F-FDG uptake.

64 In addition, 15 cardiac 18F-FDG patients (having either pacing leads, defibrilla

65 hout known cardiac disease underwent cardiac 18F-FDG-PET for assessment of arterial wall inflammation

66 ecific activity of the tracer (in this case, 18F-FDG), which are distorted because of the breathing m

67 In a prospective study, we compared 18F-FDG and L-methyl-11C-methionine (11C-methionine) PET

68 Coregistered 18F-FDG PET/CT can provide precise anatomic localization

69 Quantification of coronary 18F-FDG uptake was hampered by myocardial activity and w

70 odules by use of features extracted from CT, 18F-FDG PET, and both CT and 18F-FDG PET.

71 were, first, to analyze standard and delayed 18F-FDG PET images visually and quantitatively to determ

72 None of the missed nodules demonstrated 18F-FDG uptake.

73 To establish the optimal time during 18F-FDG uptake for blood sampling when using an SUV, a P

74 hetized and were inside the tomograph during 18F-FDG uptake, whereas 6 animals were awake in their ho

75 healthy male volunteers underwent 2 dynamic 18F-FDG PET/CT scans with an interval of 24 h.

76 nsulin treatment, reflecting the rapid early 18F-FDG uptake.

77 ur objective was to retrospectively evaluate 18F-FDG PET/CT in the initial staging of inflammatory br

78 We retrospectively evaluated 18F-FDG PET/CT for monitoring the response of non-Hodgki

79 de between animals given 124I-anti-CEA Fab', 18F-FDG, the same peptide radiolabeled with 111In and pr

80 d both positive CT and 18F-FDG PET findings, 18F-FDG PET revealed additional sites of disease.

81 ell thyroid cancer who underwent their first 18F-FDG PET scan between May 1996 and February 2003 were

82 of defining and solving standard blood flow, 18F-FDG, and receptor models as well as models of a user

83 uoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promising novel biomarkers of disease activ

84 uoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) as markers of active plaque calcification and i

85 uoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) uptake with the use of positron emission tomogr

86 In 4 patients, PET found focal 18F-FDG uptake in the brain suggestive of metastatic dis

87 ients for the input functions were 0.930 for 18F-FDG and 0.972 for 1-11C-acetate.

88 ients for the input functions were 0.973 for 18F-FDG and 0.965 for 1-11C-acetate.

89 least 1 lesion site of active metabolism for 18F-FDG or 11C-methionine, which could be used as an ind

90 1), with a more modest increase observed for 18F-FDG (r(2)=0.218, P<0.001).

91 Furthermore, 18F-FDG PET correctly classified as negative 3 patients

92 that image smearing can be reduced by gating 18F-FDG PET images in synchronization with the respirato

93 nt simulations and 18F-fluoro-deoxy-glucose (18F-FDG) positron emission tomography.

94 s missed in 1 patient who had only low-grade 18F-FDG uptake (SUVmax < 5).

95 arch has helped improve understanding of how 18F-FDG PET can best be applied.

96 Large declines in 18F-FDG uptake tend to be seen in those with the longest

97 te, there were no significant differences in 18F-FDG uptake between patients and controls for all bra

98 days 3, 14, and 21, although an increase in 18F-FDG tumor uptake of treated mice, as compared with t

99 ed and found to reduce transmission noise in 18F-FDG cardiac emission images.

100 iteria (IWC) and Revised IWC, which includes 18F-FDG PET (IWC-PET).

101 Increased 18F-FDG positron emission tomographic uptake in aortic a

102 Increased 18F-FDG uptake in DSD should not be confused with metast

103 Any increased 18F-FDG uptake was compared with the coregistered CT ima

104 8F-NaF uptake (>1.97), and 35% had increased 18F-FDG uptake (>1.63).

105 etrospectively for the presence of increased 18F-FDG uptake in the spine and for anatomic correlates.

106 strated >/=1 aneurysm wall area of increased 18F-FDG uptake.

107 In 2 patients, increased 18F-FDG uptake identified a second primary malignancy.

108 brane potential is associated with increased 18F-FDG incorporation, glucose transport, and lactate pr

109 l events occurred in patients with increased 18F-FDG uptake on their last examination than in those w

110 chondrial membrane potential could influence 18F-FDG incorporation.

111 Intense 18F-FDG uptake in lesions is an indicator of a poor prog

112 thetized animals, 6 received intraperitoneal 18F-FDG, whereas 4 received intravenous 18F-FDG, and all

113 all 6 awake animals received intraperitoneal 18F-FDG.

114 neal 18F-FDG, whereas 4 received intravenous 18F-FDG, and all 6 awake animals received intraperitonea

115 first-pass scan-and 3 sequential 15-min late 18F-FDG uptake scans.

116 One hour later, 18F-FDG was injected, followed by a 3-h dynamic PET scan

117 have developed a new technique to gate lung 18F-FDG PET images in synchronization with the respirato

118 x constant Ki as the method to quantify lung 18F-FDG uptake, we also showed that Ki correlated positi

119 In non-Hodgkin's lymphoma, 18F-FDG uptake in tumors typically drops significantly a

120 ) after the intravenous injection of 2.5 MBq 18F-FDG per kilogram of body weight.

121 a maximum regional DSD score of 3, the mean 18F-FDG uptake for that spinal level was 1.4 +/- 1.5, wh

122 died radiotracers in prostate cancer, namely 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.

123 There were 24 positive and 20 negative 18F-FDG PET scans with 1 false-positive and 1 false-nega

124 ctive study may be necessary before negative 18F-FDG PET/CT may become the only, or at least most-dec

125 Only 1 patient with negative 18F-FDG PET had positive RIS.

126 native to dynamic imaging in determining net 18F-FDG uptake during ALI.

127 In patients with neurofibromatosis, 18F-FDG-PET demonstrated its application to detect and m

128 Finally, normal 18F-FDG PET/CT excluded residual disease at the primary

129 In patients with HNSCC, normal 18F-FDG PET/CT after chemoradiotherapy has a high NPV an

130 d hepatocellular carcinoma (HCC) that is not 18F-FDG-avid.

131 The diagnostic accuracy of 18F-FDG PET/CT was evaluated for the entire patient grou

132 ll sensitivity, specificity, and accuracy of 18F-FDG PET/CT were 68.4%, 82.4%, and 73.8%, respectivel

133 tion may affect the quantitative analysis of 18F-FDG PET scans and summarizes the results of recent s

134 No significant decrease of 18F-FDG uptake was found between the treated and the con

135 h was followed by a 370-MBq (10 mCi) dose of 18F-FDG.

136 the limitations of incomplete extraction of 18F-FDG compared with 15O-water.

137 tially, PET images were examined and foci of 18F-FDG uptake in the spine were graded on a 0-4 scale b

138 The increase of 18F-FDG on day 7 was related to the inflammatory respons

139 graded on a 0-4 scale based on intensity of 18F-FDG uptake (0 = definitely normal, 1 = probably norm

140 fter intravenous injection of 400-610 MBq of 18F-FDG using a combined PET/CT scanner.

141 e intravenous injection of 383 +/- 15 MBq of 18F-FDG.

142 ravenous injection of 7.77 MBq (0.21 mCi) of 18F-FDG per kilogram of body weight, PET emission scans

143 esions (26%) had no detectable metabolism of 18F-FDG or 11C-methionine.

144 not been assessed, and the optimal method of 18F-FDG quantification is still debated.

145 ducibility measures and compare 2 methods of 18F-FDG uptake measurement.

146 due to breathing and improve quantitation of 18F-FDG uptake in lung lesions.

147 ished independently, based on the results of 18F-FDG SPECT as well as PET.

148 iterature, we evaluated the emerging role of 18F-FDG PET in staging, response assessment, risk strati

149 tlined, this article will review the role of 18F-FDG PET in the management of patients with lymphoma.

150 Four sequential scans of 18F-FDG uptake were acquired, consisting of an early 2-m

151 The sensitivities of 18F-FDG PET and 11C-methionine PET were 48% (167/348 les

152 The sensitivities of 18F-FDG PET/CT at serum thyroglobulin levels of less tha

153 C-CFN (2.42 +/- 1.17) but lower than that of 18F-FDG (7.74 +/- 0.53).

154 sue contrast is generally lower than that of 18F-FDG in most cancers outside the brain.

155 thods of quantifying the pulmonary uptake of 18F-FDG could be as powerful as calculating Ki.

156 tudy was to determine if the early uptake of 18F-FDG could be used to measure regional blood flow in

157 ormant sites followed by increased uptake of 18F-FDG during progression of disease.

158 esults suggest that the first-pass uptake of 18F-FDG may provide an estimate of perfusion in a tumor

159 lood flow estimated from the early uptake of 18F-FDG was linearly correlated with 15O-measured blood

160 of guidelines and algorithms for the use of 18F-FDG PET/CT in the evaluation and management of head

161 We investigated the clinical utility of 18F-FDG PET/CT in this setting.

162 diagnostic accuracy and prognostic value of 18F-FDG PET in this disease.

163 alone (F = 0.097, P > 0.05) had no effect on 18F-FDG uptake but ER state alone had an effect (F = 9.1

164 R being together had no additional effect on 18F-FDG uptake.

165 tionship between the severity of findings on 18F-FDG PET and the severity of degenerative spinal dise

166 Thirty patients had positive findings on 18F-FDG PET/CT; 26 were true-positive and 4 were false-p

167 oor contrast resolution and were not seen on 18F-FDG PET because of higher background uptake relative

168 ancer confirms the utility of the first-pass 18F-FDG blood flow analysis in tumor diagnosis.

169 In patients, 18F-FDG scans also were performed.

170 Dual time point 18F-FDG PET results in a very high sensitivity and speci

171 G PET scanning with those of dual time point 18F-FDG PET scanning.

172 Ten patients with positive 18F-FDG PET had negative RIS.

173 MTV and TLG was calculated from preoperative 18F-FDG PET/CT scans and analyzed as marker of biochemic

174 a follow-up of up to 5.9 y after prospective 18F-FDG PET imaging.

175 and maximum TBR measurements for quantifying 18F-FDG uptake are equally reproducible.

176 Quantitatively, 18F-FDG positron emission tomographic uptake correlated

177 Semiquantitative analysis of regional 18F-FDG uptake was performed in both cortical and subcor

178 In 3 of 6 patients with positive RIS, 18F-FDG PET revealed additional sites of metastatic dise

179 determined the prevalence of abnormal spinal 18F-FDG uptake and assessed the relationship between the

180 compares the diagnostic accuracy of standard 18F-FDG PET scanning with those of dual time point 18F-F

181 of 7 patients underwent an additional static 18F-FDG PET scan for clinical indications.

182 T identified significantly more lesions than 18F-FDG PET (P < 0.01).

183 The 18F-FDG tumor extraction fraction relative to 15O-water

184 the areas under the curves (AUCs) and in the 18F-FDG influx constant Ki in 3 types of tissue.

185 anied by an increase in the intensity in the 18F-FDG signal per voxel.

186 excellent short-term reproducibility of the 18F-FDG signal, with intraclass correlation coefficients

187 al protocol in which animals can receive the 18F-FDG tracer injection intraperitoneally, away from th

188 Consequently, 18F-FPPRGD2 PET is superior to 18F-FDG PET in monitoring early response to treatment, f

189 al skeleton MRI have been proven superior to 18F-FDG PET/computed tomography.

190 rodeoxyglucose positron emission tomography (18F-FDG PET) imaging in the follow-up of patients with d

191 rodeoxyglucose positron emission tomography (18F-FDG-PET) is being used with increased frequency in t

192 Changes in tumor 18F-FDG uptake correlate significantly with histopatholo

193 A typical 18F-FDG clinical brain study requires only 2 mCi to achi

194 h Hurthle cell thyroid cancer should undergo 18F-FDG PET as part of their initial postoperative stagi

195 0Y-ibritumomab tiuxetan (n=10) and underwent 18F-FDG PET/CT scans before radioimmunotherapy and at 12

196 with newly diagnosed breast cancer underwent 18F-FDG PET (5.2 MBq/kg of body weight).

197 cal suspicion of recurrent disease underwent 18F-FDG PET/CT.

198 nts with lymph node metastases who underwent 18F-FDG PET/CT > or = 8 wk after the end of therapy were

199 -71 y) and newly diagnosed IBC who underwent 18F-FDG PET/CT at diagnosis were retrospectively reviewe

200 formed of 37 patients with CLL who underwent 18F-FDG PET/CT at our institution between March 2003 and

201 aged 20 patients with vascular disease using 18F-FDG PET twice, 14 d apart, and used these data to as

202 e mean U87MG tumor volume was 35.0 mm3 using 18F-FDG and 34.1 mm3 with 11C-MeAIB, compared with 33.7

203 nding T87 tumor volumes were 122.1 mm3 using 18F-FDG, 118.3 mm3 with 11C-MeAIB, and 125.4 mm3 by hist

204 histology-derived volumes was obtained using 18F-FDG, MAP3D reconstruction, and fixed thresholding of

205 udy was to evaluate the feasibility of using 18F-FDG and PET for the detection of infection associate

206 PET using 18F-FDG has been shown to effectively detect various typ

207 of PET in myocardial viability studies using 18F-FDG.

208 icant correlation was noted between valvular 18F-FDG uptake and change in calcium score (r=-0.11; P=0

209 Vessel 18F-FDG uptake was measured as both the mean and maximum

210 toparietal cortical brain perfusion, whereas 18F-FDG cerebral uptake was normal.

211 With 18F-FDG, PET/CT is rapidly becoming the key investigativ

212 nsisted of a 60-min dynamic acquisition with 18F-FDG (18.5-29.6 MBq).

213 major clinical need is being addressed with 18F-FDG PET/CT, because of its inherent ability to demon

214 oving targeting specificity as compared with 18F-FDG.

215 PET/CT with 18F-FDG is increasingly being used for staging, restagin

216 Dynamic PET imaging with 18F-FDG (7.7+/-0.9 MBq) was conducted.

217 6 BALB/c mice underwent dynamic imaging with 18F-FDG (n = 6) and 1-11C-acetate (n = 6).

218 Whole-body PET imaging with 18F-FDG has been used successfully to stage colorectal c

219 Imaging with 18F-FDG PET is increasingly accepted as a valuable tool

220 Atherosclerosis imaging with 18F-FDG PET is useful for tracking inflammation within p

221 lished indication for metabolic imaging with 18F-FDG.

222 delineation of gliomas from gray matter with 18F-FDG PET could be improved by extending the interval

223 of the incorporation of regional nodes with 18F-FDG avidity that were previously judged to be uninvo

224 ng disease-specific metabolism patterns with 18F-FDG PET compared with that of clinical diagnosis.

225 PET with 18F-FDG has gained a role in the staging and follow-up o

226 eted a trial evaluating the role of PET with 18F-FDG in patients with documented or suspected non-sma

227 PET with 18F-FDG may be useful for quantifying neutrophilic activ

228 too small to be characterized reliably with 18F-FDG PET.

229 arotid artery cannulations were studied with 18F-FDG small-animal PET accompanied by serial arterial

230 pretargeted animals less ambiguous than with 18F-FDG.

231 Tumor visualization with 18F-FDG at approximately 1.5 h was also good but showed